NovAliX has entered into a pharma alliances agreement, for development of fragment-based drug discovery, with bigpharma Kyowa Hakko Kirin.
Within this pharma alliances agreement, the companies will collaborate to develop novel drug candidates against protein-protein interaction targets.
NovAliX will generate novel lead candidates using the broad spectrum of its biophysical capabilities and its medicinal chemistry expertise as discussed in this pharma alliances deal.
Under the terms of the agreement NovAliX will receive technology access fees as well as further research funding payments and milestones
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Kyowa Hakko Kirin
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity